
Sign up to save your podcasts
Or
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.
4.7
77 ratings
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.
8,798 Listeners
1,618 Listeners
1,869 Listeners
247 Listeners
563 Listeners
256 Listeners
3,181 Listeners
844 Listeners
420 Listeners
208 Listeners
407 Listeners
150 Listeners
799 Listeners
27 Listeners
71 Listeners